PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer

• Ētahi atu kaituhi: Curtin, Nicola (Editor), Bay, Péter (Editor)
• Hōputu: Tāhiko Wāhanga pukapuka
• Reo: Ingarihi
• I whakaputaina: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
• Ngā marau: Research & information: general; Biology, life sciences; Biochemistry; MDS; PARP inhibitors; olaparib; hematopoietic differentiation; PARP1; AML; poly-ADP-ribose polymerase 1 (PARP1); brahma-related gene 1 (BRG1); histone acetyltransferase p300 (EP300); gene transcription; cancer cell; head and neck squamous cell carcinoma; CAL27; SCC90; p60/p150 CAF-1 subunits; DNA repair; homologous recombination; biomarkers; personalized treatment; UVB; PARP; mitochondria; metabolism; biogenesis; autophagy; carcinogenesis; transcription; PARylation; DNA damage; transcription silencing; carryover effect; TOP1 activity; TDP1; irinotecan; immunomodulation; tumor microenvironment; trapping; cancer therapeutic strategy; arginine-specific mono-ADP-ribosylation; bacterial toxin; cholera toxin; ART1; ARH1; tumorigenesis; loss of heterozygosity; membrane repair; gender bias; Syk; EGFR; squamous cell carcinoma; PARP-Akt interplay; PI3K; mTOR; cytoprotection; apoptosis resistance; oxidative stress; mitochondrial protection; drug development; synthetic lethality; clinical trials; ADP-ribosylation; cancer; macrodomain; ADP-ribosyl hydrolase; ARTD; MACROD1; MACROD2; TARG1; ATM; ATR; PARP inhibitor; prostate cancer; pancreatic cancer; lung cancer; Tumor microenvironment; PARPs; hypoxia; CHK1; replication stress; homologous recombination DNA repair; cell cycle; cytotoxicity; PARP Inhibitors; beta-lapachone; NQO1; PARG; NAMPT; cancer therapeutics; cMET; poly (ADP-ribose) glycohydrolase; radiosensitization; poly (ADP-ribose) polymerase; ES cells; poly (ADP-ribose) polymerase inhibitors (PARPi); ataxia telangiectasia and Rad3 related inhibitors (ATRi); cell cycle checkpoints; NAD+; NMNAT1; cisplatin; chemotherapy; apoptosis; osteosarcoma; DNA damage response; immunotherapy; immune checkpoint inhibitor; PD-1; PD-L1; CTLA-4; combination therapy; solid tumors; the PARP inhibitor PJ34; distorted mitotic spindles; exclusive eradication of human cancer cells; nucleolus; poly(ADP-ribosyl)ation; ARTDs; n/a
• Urunga tuihono: DOAB: download the publication; DOAB: description of the publication

This Special Issue of Cancers contains research and review articles on "PARPs, PAR and NAD metabolism and their inhibitors in Cancer". It focuses on selected papers from the PARP2019 conference on "New Avenues in Basic and Translational PARP research", that took place in Budapest...